MTOR and glioma: Thereof, designing targeted therapies that can enhance the levels of ROS and impede glioma proliferation via inhibition of PI3K/AKT/mTOR pathway are vitally important as they might improve glioma patient therapeutic outcome (Taylor et al., 2019).